Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Madrigal Pharmaceuticals (MDGL) Accounts Payables: 2010-2024

Historic Accounts Payables for Madrigal Pharmaceuticals (MDGL) over the last 11 years, with Dec 2024 value amounting to $43.6 million.

  • Madrigal Pharmaceuticals' Accounts Payables fell 2.23% to $44.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $44.9 million, marking a year-over-year decrease of 2.23%. This contributed to the annual value of $43.6 million for FY2024, which is 55.48% up from last year.
  • Madrigal Pharmaceuticals' Accounts Payables amounted to $43.6 million in FY2024, which was up 55.48% from $28.0 million recorded in FY2023.
  • Madrigal Pharmaceuticals' 5-year Accounts Payables high stood at $43.6 million for FY2024, and its period low was $1.0 million during FY2020.
  • In the last 3 years, Madrigal Pharmaceuticals' Accounts Payables had a median value of $28.0 million in 2023 and averaged $31.8 million.
  • In the last 5 years, Madrigal Pharmaceuticals' Accounts Payables decreased by 13.67% in 2020 and then spiked by 2,002.26% in 2021.
  • Over the past 5 years, Madrigal Pharmaceuticals' Accounts Payables (Yearly) stood at $1.0 million in 2020, then skyrocketed by 2,002.26% to $21.4 million in 2021, then rose by 11.46% to $23.8 million in 2022, then rose by 17.67% to $28.0 million in 2023, then spiked by 55.48% to $43.6 million in 2024.